The platelet proteasome and immunoproteasome are stable in buffy-coat derived platelet concentrates for up to 7 days.
platelet aggregation
platelet concentrate
proteasome system
storage lesions
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
20
06
2021
received:
30
06
2020
accepted:
27
06
2021
pubmed:
1
8
2021
medline:
9
11
2021
entrez:
31
7
2021
Statut:
ppublish
Résumé
Characterization of the proteasome and its stability in buffy-coat derived platelet concentrates (PCs) during storage. The proteasome plays a key role in cell homeostasis by processing misfolded or abnormal proteins and regulating the levels and activities of a high number of proteins contributing to cell cycle, survival, and proliferation. Controversial data exist, whether inhibition of the proteasome affects platelet function. Little is known about function, expression, and stability of the proteasome in PCs during storage, and the potential role of the platelet proteasome in storage lesions. PCs were produced by the buffy-coat method in additive solution and stored at room temperature under agitation. Platelet aggregation was monitored by light transmission aggregometry. Proteasome complexes were assessed by immunoprecipitation and immunoblotting, and proteasome activity was measured using fluorogenic substrates specific for the three different proteolytic activities over 7 days of storage. Proteasome inhibition led to a decreased platelet aggregation response after activation with collagen, ADP, TRAP-6, and thrombin. There were no changes in the expression of the catalytic active subunits as well as the proteasome activity during storage of PCs, comparing baseline and day 7. Platelet proteasome function is relevant for platelet aggregation in response to various agonists. The constitutive and stable expression of the active standard- and immunoproteasome in platelets makes it unlikely that loss of proteasome function is a relevant cause of storage lesions.
Sections du résumé
OBJECTIVES
Characterization of the proteasome and its stability in buffy-coat derived platelet concentrates (PCs) during storage.
BACKGROUND
The proteasome plays a key role in cell homeostasis by processing misfolded or abnormal proteins and regulating the levels and activities of a high number of proteins contributing to cell cycle, survival, and proliferation. Controversial data exist, whether inhibition of the proteasome affects platelet function. Little is known about function, expression, and stability of the proteasome in PCs during storage, and the potential role of the platelet proteasome in storage lesions.
STUDY DESIGN AND METHODS
PCs were produced by the buffy-coat method in additive solution and stored at room temperature under agitation. Platelet aggregation was monitored by light transmission aggregometry. Proteasome complexes were assessed by immunoprecipitation and immunoblotting, and proteasome activity was measured using fluorogenic substrates specific for the three different proteolytic activities over 7 days of storage.
RESULTS
Proteasome inhibition led to a decreased platelet aggregation response after activation with collagen, ADP, TRAP-6, and thrombin. There were no changes in the expression of the catalytic active subunits as well as the proteasome activity during storage of PCs, comparing baseline and day 7.
DISCUSSION
Platelet proteasome function is relevant for platelet aggregation in response to various agonists. The constitutive and stable expression of the active standard- and immunoproteasome in platelets makes it unlikely that loss of proteasome function is a relevant cause of storage lesions.
Substances chimiques
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2746-2755Informations de copyright
© 2021 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Periayah MH, Halim AS, Mat Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res. 2017;11:319-27.
Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001;12:261-73.
Binsker U, Palankar R, Wesche J, Kohler TP, Prucha J, Burchhardt G, et al. Secreted immunomodulatory proteins of Staphylococcus aureus activate platelets and induce platelet aggregation. Thromb Haemost. 2018;118:745-57.
Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010;30:2341-9.
Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-47.
Tanaka K, Mizushima T, Saeki Y. The proteasome: molecular machinery and pathophysiological roles. Biol Chem. 2012;393:217-34.
Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2:179-87.
Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13-21.
Vigneron N, Van den Eynde BJ. Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules. 2014;4:994-1025.
Kniepert A, Groettrup M. The unique functions of tissue-specific proteasomes. Trends Biochem Sci. 2014;39:17-24.
Gu ZC, Enenkel C. Proteasome assembly. Cell Mol Life Sci. 2014;71:4729-45.
Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997;386:463-71.
Lupas A, Zwickl P, Wenzel T, Seemuller E, Baumeister W. Structure and function of the 20S proteasome and of its regulatory complexes. Cold Spring Harb Symp Quant Biol. 1995;60:515-24.
Murata S, Takahama Y, Kasahara M, Tanaka K. The immunoproteasome and thymoproteasome: functions, evolution and human disease. Nat Immunol. 2018;19:923-31.
Angeles A, Fung G, Luo H. Immune and non-immune functions of the immunoproteasome. Front Biosci (Landmark Ed). 2012;17:1904-16.
Klockenbusch C, Walsh GM, Brown LM, Hoffman MD, Ignatchenko V, Kislinger T, et al. Global proteome analysis identifies active immunoproteasome subunits in human platelets. Mol Cell Proteomics. 2014;13:3308-19.
Kraemer BF, Weyrich AS, Lindemann S. Protein degradation systems in platelets. Thromb Haemost. 2013;110:920-4.
Colberg L, Cammann C, Greinacher A, Seifert U. Structure and function of the ubiquitin-proteasome system in platelets. J Thromb Haemost. 2020;18:771-80.
Gupta N, Li W, Willard B, Silverstein RL, McIntyre TM. Proteasome proteolysis supports stimulated platelet function and thrombosis. Arterioscler Thromb Vasc Biol. 2014;34:160-8.
Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121:567-71.
Koessler J, Etzel J, Weber K, Boeck M, Kobsar A. Evaluation of dose-dependent effects of the proteasome inhibitor bortezomib in human platelets. Eur J Pharmacol. 2016;791:99-104.
Grundler K, Rotter R, Tilley S, Pircher J, Czermak T, Yakac M, et al. The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NFkB) activation. Thromb Res. 2016;148:15-22.
Karim ZA, Vemana HP, Khasawneh FT. MALT1-ubiquitination triggers non-genomic NF-kappaB/IKK signaling upon platelet activation. PLoS One. 2015;10:e0119363.
Lee VS, Tarassenko L, Bellhouse BJ. Platelet transfusion therapy: platelet concentrate preparation and storage. J Lab Clin Med. 1988;111:371-83.
Isola H, Ravanat C, Rudwill F, Pongerard A, Haas D, Eckly A, et al. Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for 7 days, with or without INTERCEPT pathogen reduction. Transfusion. 2021;61:919-30.
Thon JN, Schubert P, Devine DV. Platelet storage lesion: a new understanding from a proteomic perspective. Transfus Med Rev. 2008;22:268-79.
Devine DV, Serrano K. The platelet storage lesion. Clin Lab Med. 2010;30:475-87.
Schubert P, Devine DV. Towards targeting platelet storage lesion-related signaling pathways. Blood Transfus. 2010;8(Suppl 3):s69-72.
Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev. 1997;11:130-44.
Seghatchian J. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers. Transfus Apher Sci. 2006;34:125-30.
Bennett JS. Shedding new light on the platelet storage lesion. Arterioscler Thromb Vasc Biol. 2016;36:1715-6.
Árnason NÁ, Sigurjónsson ÓE. New strategies to understand platelet storage lesion. ISBT Sci Ser. 2017;12:496-500.
Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion. 2003;43:526-35.
Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion. 2003;43:2-6.
Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave JP, et al. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000;84:484-91.
Bergmeier W, Burger PC, Piffath CL, Hoffmeister KM, Hartwig JH, Nieswandt B, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003;102:4229-35.
Canault M, Duerschmied D, Brill A, Stefanini L, Schatzberg D, Cifuni SM, et al. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood. 2010;115:1835-42.
Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007;5:1530-7.
Dasgupta SK, Argaiz ER, Mercado JE, Maul HO, Garza J, Enriquez AB, et al. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010;50:2167-75.
Ebstein F, Lange N, Urban S, Seifert U, Kruger E, Kloetzel PM. Maturation of human dendritic cells is accompanied by functional remodelling of the ubiquitin-proteasome system. Int J Biochem Cell Biol. 2009;41:1205-15.
Kaltoft MB, Koch C, Uerkvitz W, Hendil KB. Monoclonal antibodies to the human multicatalytic proteinase (proteasome). Hybridoma. 1992;11:507-17.
Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N. Mechanism of action of Bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int. 2015;2015:172458.
Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol. 2012;199:583-8.
Guo N, Peng Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 2013;9:6-11.
Dasgupta S, Castro LM, Dulman R, Yang C, Schmidt M, Ferro ES, et al. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells. PLoS One. 2014;9:e103604.
Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71:170-97.
Gupta A, Chandra T, Kumar A. Retracted: platelet storage lesion: current proteomics approach. Platelets. 2011;22:117-34.
Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015;7:1011-22.
Koessler J, Schuepferling A, Klingler P, Koessler A, Weber K, Boeck M, et al. The role of proteasome activity for activating and inhibitory signalling in human platelets. Cell Signal. 2019;62:109351.
Klingler P, Niklaus M, Koessler J, Weber K, Koessler A, Boeck M, et al. Influence of long-term proteasome inhibition on platelet responsiveness mediated by bortezomib. Vascul Pharmacol. 2021;138:106830.
Guo L, Shen S, Rowley JW, Tolley ND, Jia W, Manne BK, et al. Platelet MHC class I mediates CD8+ T cell suppression during sepsis. Blood. 2021.
Heink S, Ludwig D, Kloetzel PM, Kruger E. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A. 2005;102:9241-6.
Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443-6.
Osman A, Hitzler WE, Meyer CU, Landry P, Corduan A, Laffont B, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets. 2015;26:154-63.
Hendil KB, Uerkvitz W. The human multicatalytic proteinase: affinity purification using a monoclonal antibody. J Biochem Biophys Methods. 1991;22:159-65.